Haskel William M.'s Form 4 filing

Paratek Pharmaceuticals, Inc. (PRTK) · filed Dec 14, 2022

Accession no.: 0000904454-22-000625
Filed: Dec 14, 2022
Trade date: Dec 12-13, 2022
Filing delay: 2 days
Rule 10b5-1 plan: Not on the form (before 2023)

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market sales total $74.8K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Haskel William M.CIK 0001524372	Officer (CLO, General Counsel & Sec.)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Dec 12, 2022	Common Stock	SSaleDisposed	−14,410	$1.98^F2	−$28,531.8	423,391	Direct
Dec 13, 2022	Common Stock	SSaleDisposed	−23,584	$1.96^F3	−$46,224.64	399,807	Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.96 to $2.00. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4.

Referenced by the price of 1 transaction in Table I.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.93 to $2.01. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)